uptodate

https://www.uptodate.com/contents/covid-19-management-in-hospitalized-adults#:~:text=In%20a%20meta%2Danalysis%20of,severe%20adverse%20events%20%5B45%5D.

 

Dexamethasone and other glucocorticoids

●Use of dexamethasone – We recommend dexamethasone for severely ill patients with COVID-19 who are on supplemental oxygen or ventilatory support (algorithm 2). We use dexamethasone at a dose of 6 mg daily for 10 days or until discharge, whichever is shorter. If dexamethasone is not available, it is reasonable to use other glucocorticoids at equivalent doses (eg, total daily doses of hydrocortisone 150 mg, methylprednisolone 32 mg, or prednisone 40 mg), although data supporting use of these alternatives are more limited than those for dexamethasone. In contrast, we recommend that dexamethasone (or other glucocorticoids) not be used for either prevention or treatment of mild to moderate COVID-19 (patients not on oxygen). These recommendations are largely consistent with those of other expert and governmental groups [2,41-44]. (See 'Patients with oxygen requirement/severe disease' above.)

 

Glucocorticoids may also have a role in the management of refractory shock in critically ill patients with COVID-19. These issues are discussed elsewhere. (See "COVID-19: Management of the intubated adult", section on 'Use of glucocorticoids for non-COVID-19 reasons'.)